HCPCS Level II
J0578
Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy
Codes near J0578
These sit next to J0578 in the CMS Level II file. All J codes
- J0573Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine
- J0574Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine
- J0575Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine
- J0576Injection, buprenorphine extended-release (brixadi), 1 mg
- J0577Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy
- J0582Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
- J0583Injection, bivalirudin, 1 mg
- J0584Injection, burosumab-twza 1 mg
- J0585Injection, onabotulinumtoxina, 1 unit
- J0586Injection, abobotulinumtoxina, 5 units
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 58284-0228-01 | Brixadi (monthly dosing) | Braeburn Inc. | 1 |
| 58284-0264-01 | Brixadi (monthly dosing) | Braeburn Inc. | 1 |
| 58284-0296-01 | Brixadi (monthly dosing) | Braeburn Inc. | 1 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.